Price
No data yet.
Social Signal Score
Analyst Ratings
16 analystsRevenue
$72.46MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Elizabeth Barrett
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 300
- Beta
- 1.58
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -1.77
Financials
Revenue
$72.46M+313.3%Net Income
$-14.35MEBITDA
$-3.76MFree Cash Flow
$-33.07MEPS (diluted)
$-0.28Shares Outstanding (diluted)
50.38M+320.8%Operating Expenses
$65.77MCash & Debt
$107.97MReturn of Capital
$0.00Revenue by Segment (annual)
$93.99MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $109.79M | $-153.49M | $-3.19 |
| 2024 | $90.40M | $-126.87M | $-2.96 |
| 2023 | $82.71M | $-102.24M | $-3.55 |
| 2022 | $64.36M | $-109.78M | $-4.79 |
| 2021 | $48.04M | $-110.82M | $-4.96 |
| 2020 | $11.80M | $-128.48M | $-5.90 |
| 2019 | $18.0K | $-105.15M | $-4.90 |
| 2018 | $1.13M | $-75.66M | $-4.80 |
| 2017 | $8.16M | $-20.00M | $-2.06 |
| 2016 | $17.53M | $-1.94M | $-0.16 |
| 2015 | $0.00 | $-12.69M | $-5.51 |
| 2014 | $0.00 | $-4.56M | $-1.98 |
| 2013 | $0.00 | $-3.31M | $-1.56 |
Valuation
URGNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (6)
- Newszacks.com·5d ago·Neutral
Here's Why You Should Add URGN Stock to Your Portfolio Now UroGen's Zusduri sales surge, Jelmyto revenues and advancing pipeline assets strengthen its shift toward a commercial growth story.
View source ↗ - Newszacks.com·45d ago·Neutral
Wall Street Analysts Think Urogen Pharma (URGN) Could Surge 27.14%: Read This Before Placing a Bet The consensus price target hints at a 27.1% upside potential for Urogen Pharma (URGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
View source ↗ - Newsprnewswire.com·47d ago·Positive
…ctables, today announced an equity investment agreement and a strategic Option and Research License Agreement (the Option Agreement) with UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers.
View source ↗ - Newsglobenewswire.com·47d ago·Neutral
UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline Collaboration grants UroGen a research license and exclusive options to license and develop up to three oncology products utilizing IntraGel's proprietary SRGel platform Agreement also includes an exclusive option to acquire worldwide rights to TumoCure, an investigational therapy for advanced head and neck cancer PRINCETON, N.J., Au
View source ↗ - Newsglobenewswire.com·50d ago·Neutral
UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC PRINCETON, N.J., Aug. 17, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
View source ↗ - Newszacks.com·52d ago·Neutral
Are You Looking for a Top Momentum Pick? Why Urogen Pharma (URGN) is a Great Choice Does Urogen Pharma (URGN) have what it takes to be a top stock pick for momentum investors? Let's find out.
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $0.10 per share
Typical surprise -5.7% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$-0.28 vs $-0.27miss
- Wed, May 6$-0.47 vs $-0.56beat
- Mon, Mar 2$-0.54 vs $-0.52miss
- Thu, Nov 6$-0.69 vs $-0.72beat
- Thu, Aug 7$-1.05 vs $-0.82miss
- Mon, May 12$-0.92 vs $-0.83miss
Estimates and results for URGN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by URGN officers and directors.
- Bought
- —
- Sold
- $5.3m
0 trades
24 trades
- Schoenberg Marksold
- Smith Jason Drewsold
- Schoenberg Marksold
- Schoenberg Marksold
- Schoenberg Marksold
- Schoenberg Marksold
- Schoenberg Marksold
- Smith Jason Drewsold
76 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in URGN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.